NCT02680314View on ClinicalTrials.gov

Is More Than One Dose of Misoprostol Needed to Expedite Vaginal Delivery in a Patient With an Unripe Cervix?

PHASE2CompletedINTERVENTIONAL

Enrollment

243

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

May 17, 2017

Study Completion Date

June 16, 2021

Conditions

Labor; Forced or Induced, Affecting Fetus or Newborn

Interventions

DRUG

Misoprostol

Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.

All Listed Sponsors

lead

Montefiore Medical Center

OTHER

NCT02680314 - Is More Than One Dose of Misoprostol Needed to Expedite Vaginal Delivery in a Patient With an Unripe Cervix? | Biotech Hunter | Biotech Hunter